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Abstract   
 
Introduction: As genomic sequencing become more efficient and cost-effective, the number 
of conditions identified through newborn screening globally is set to dramatically increase. 
Haemophilia is a candidate condition, however very little is known about the attitudes of 
the haemophilia community towards screening. 
Aim: This study aimed to outline the perspectives of adults with haemophilia and their 
families towards newborn screening. 
Methods: A paper and online survey on screening was distributed to every family known to 
the Haemophilia Society UK. Data collection occurred between January and June 2018. In 
total, 327 participants completed the survey: 76% were a relative of a person with 
haemophilia and 24% had haemophilia themselves; 83% were living with haemophilia A and 
17% with haemophilia B. 
Results: The vast majority supported newborn screening (77%) and preferred it to other 
forms of screening (pre-conception or prenatal). Participants supported newborn screening 
primarily because they viewed it as a means to facilitate early support and treatment, 
facilitate informed decisions about future pregnancies and prevent the ‘diagnostic odyssey’. 
The 23% who did not support the screen did not associate these particular benefits with 
newborn screening. 
Conclusion:  Haemophilia emerged from this analysis as a condition that the vast majority of 
participants considered a ‘liveable’ disability and one best suited to newborn screening 
programmes that could improve support to affected families rather than reduce the birth 
rate of affected children.   
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INTRODUCTION 
Rapid developments in genomic technologies now mean that it is possible to screen 
newborn babies for larger numbers of conditions simultaneously than ever before. The 
development of tandem mass spectrometry, and the declining cost and increasing efficacy 
of whole genome/exome sequencing using technologies such as CRISPR-Cas9 now mean 
that high output mass screens are on the horizon, prompting renewed interest in the 
potential population health and societal benefits of population-based genomic screens1,2,3,4.  
By conducting untargeted genome/exome sequencing, whole panels of genetic conditions 
can now be screened for from a single blood sample, as well as child’s propensity to future 
diseases, and even their potential reactions to certain medicines and drugs. As such, direct-
to-consumer private genetics companies are aready capitalising on the value of this 
information to new parents by offering expansive newborn screens for a nominal fee. 
 
Haemophilia is a potential candidate condition for newborn screening being expanded to 
the general population, who have no known family history of the condition. Affecting one in 
every 5000 male newborns worldwide (haemophilia A) and 1 in 30,000 male newborns 
(haemophilia B), it is the most severe form of X-linked inherited bleeding disorder. 
Moreover, as the most serious type of bleed for those with haemophilia (intracranial 
haemorrhage) is most likely to occur during the neonatal period, and with about half of 
these babies having no family history of a bleeding disorder, newborn screening for the 
condition can also be justified on the grounds of protecting the health of both the infant, 
but also the mother who may have some bleeding symptoms5.  
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Given the perceived disease burden associated with haemophilia, however, research into 
population screening has previously generally focused attention on the prenatal or pre-
conception period rather than the newborn period6. However, with the advent of new 
treatments, particularly early prophylactic treatment that uses recombinant clotting factors, 
means that the disease burden of haemophilia is slowly evolving, altering the landscape of 
genetic screening7. Indeed, the frequently observed contrast between the experiences of 
younger generations growing up with haemophilia and those of older generation 
haemophiliacs -many of whom were exposed to blood borne viruses such as Hepatitis B/C 
and HIV through contaminated blood in the 1970s and 1980s- suggests that an exploration 
of current attitudes towards screening for haemophilia amongst the affected community is 
now particularly timely8,9.  
Whilst the acceptability of newborn screens to (expectant) parents is a topic that has been 
widely explored in relation to a range of different conditions10,11,12, and is a key component 
in the assessment of screening programmes conducted by the UK National Screening 
Committee14, the views of  affected families and adults has been less extensively 
researched10,12,15,16. This omission is striking given that the ‘hands on’ direct experience 
possessed by these families uniquely positions them to consider what an early screen would 
have meant for them10. Furthermore, screening has impacts for affected families that go 
beyond those anticipated for the general population. These include the social implications 
(for example, stigmatisation) that come along with a shift in the ‘public profile’ of the 
condition17, but also a potential decrease in the condition’s prevalence (as has already been 
observed in relation to Cystic Fibrosis since the introduction of newborn screening 18) , with 
associated implications for how the condition is prioritised in the context of the allocation of 
public funding for research into treatments19.   
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To address this identified gap in the literature, this study presents data on attitudes towards 
newborn genetic screening amongst people living with haemophilia A and/or B, either 
through having the condition themselves, or having affected relatives. By drawing on a 
national UK survey of families living with haemophilia, this paper contributes to an emerging 
area of the literature that considers the social and ethical of dimensions of screening 
practices from the vantage point of those already living with the disease10, 12, 15, 16, 18.  
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MATERIALS AND METHODS 
This study reports on quantitative data that formed part of a larger exploratory 
sequential mixed methods study on attitudes to different types of screening programme 
across families living with various genetic conditions12,20,21.  
 
Through the use of an advertisement in the newsletter of the  UK Haemophilia 
Society, 22 adults with haemophilia and family members of people with haemophilia were 
recruited to participate in qualitative interviews that took place between April 2017 and 
March 2018. Seventeen interviews were conducted by telephone and four interviews were 
conducted in person. The interview participants varied in terms of their ages, backgrounds 
and  experiences with haemophilia as well co-morbidities (associated with contaminated 
blood). The final sample included eight males with haemophilia and fifteen female relatives.  
The interviews explored participants’ experiences with haemophilia, their views on the 
condition’s impact and their experiences of, and attitudes towards, reproductive genetic 
technoloiges. A thematic analysis was carried out on the qualitative interviews, and a 
survey, the Haemophilia Screening Survey (UK), directly developed from this analysis in 
order to measure both the significance and generalisability of the expressed ideas. The core 
themes were used to delineate the key domains of the survey, and, where possible, 
verbatim data extracts from interview participants were used to create attitude statement 
questions, accompanied by a lickert scale. Demographic questions were replicated, or 
appear as modified versions of  those included in the 2011 UK Census survey. Ethical 
approval for the survey was granted by the Biomedical and Scientific Research Ethics 
Committee in November 2017. 
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Survey data collection took place between January and June 2018. Participants were invited 
to complete it if they either had haemophilia A or B themselves or had the condition in their 
family. No restrictions were placed on the nature of the familial relationship, so step, 
adopted and fostered family members were all included.  
 
A paper version of the survey was initially mailed to the 3,000 households affected by 
haemophilia that were known to the Haemophilia Society UK, and an online version was 
made available and distributed through the Haemophilia Society’s online networks. The link 
was also disseminated through the social networks associated with the research project. 
Participants were encouraged to distribute the survey to relevant family/friends. Postal 
survey returns were all processed using data scanning technology to reduce human error. 
 
 
The attitudes of family members and adults with  hemophilia (AwH) towards 
newborn genetic screening (NGS) were compared to determine if there were any statistical 
differences using a chi-squared analysis (Graphpad Prism software, v6).  
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RESULTS 
Demographic Data 
In total, 327 people returned either an online (33/327) or postal survey (294/327). 
Of these, 148/327 (45% ) were family members and 179/327 (55%) were AwH (Table 1); 
173/327 (53%) participants were male (Table 1), including 21/148 (14%) family members 
and 152/179 (85%) AwH (Table 1). Overall, most participants were associated with 
haemophilia A (273/327, 83%), broken down into 127/148 (86%) family members and 
146/179 (82%) AwH (Table 1). 
 
Newborn Genetic Screening (NGS) 
Overall, 253/327 (77%) supported NGS. However, there was a tendency towards less 
support for NGS in AwH: 132/179 (74%) than family members (Families: 121/148 (82%); 
Table 2).  
 
The key reasons driving support for NGS was a belief that it would lead to better support, 
would allow parents to make informed decisions about future pregnancies and would spare 
parents the difficulties associated with a later diagnosis (Table 2). Participants also believed 
than an early screen could extend life expectancy and would allow earlier enrolment on 
clinical trials (Table 2). Most participants agreed that NGS is important even if severity could 
not be determined accurately at birth in all cases (Table 2).  
 
Less than half of the participants agreed that NGS is unethical because of the lack of 
curative treatment available (a common ethical argument used against the introduction of 
NGS) or the notion that by using NGS, and not other forms of screening (such as pre-
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conception or prenatal screening), that NGS denies parents the choice as to whether or 
not they want to bring children affected by haemophilia into the world in the first 
place  (Table 2). Similarly, less than half the sample agreed that newborn screening would 
stop families and children enjoying life whilst they were still symptom free and most 
disagreed with the idea that receipt of a serious diagnosis early in life would interfere with 
parent-child bonding (Table 2).  
 
Interestingly, no significant differences in support for NGS were observed between those 
participants who came from families with multiple (>2) affected members as compared to 
those families who had only one or two members with haemophilia (Table 3).  
 
74/327 (23%) responders did not support NGS: 27/148 (18%) families and 47/179 (26%) 
AwH (Table 4). Sub-analysis of these responders highlights that in general they did not 
believe introducing NGS would extend life expectancy or increase enrolment on clinical trial. 
However, although these 23% of responders did not personally support NGS introduction, 
they did not believe NGS would reduce pre-symptomatic quality of life, interfere with the 
parent-child bonding process, make the diagnosis easier to accept for the parents or believe 
that it is unethical to screen newborn babies for diseases that cannot be treated (Table 4).   
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DISCUSSION 
 This study, to the best of our knowledge, is the first to explore attitudes towards 
newborn screening amongst families and AwH. It has revealed that most adults with, and 
families affected by, haemophilia are in favour of newborn screening for the condition.  
With the increasing use of whole genome sequencing techniques for screening purposes, 
the introduction of newborn screening for conditions such as haemophilia could mark the 
advent of a new era in the management of the condition, including the possibility of using 
new non-factor drugs on these patients with very early diagnoses. Indeed, even the 23% of 
participants who did not support newborn screening in this study did so not because they 
necessarily held negative beliefs about newborn screening (for example, that it may affect 
parent/child bonding or extend the illness into the pre-symptomatic period) but rather 
because they were unconvinced that newborn screening would confer the particular 
advantages cited by screening supporters. As such, this study did not uncover overtly 
negative views about this type of screening programme. 
There were some differences, however, in responses between AwH, who are mostly male, 
and responding family members, who are mostly female, with female relatives more likely 
to support NGS than affected males;although this differences are not significant, they are 
approaching significance (p=0.08). It is possible that this difference highlights the scepticism 
on the part of AwH regarding any tangible differences that NGS would have made to their 
own lives, particularly as none of them had benefitted from the early interventions offered 
to boys with haemophilia today, such as the commencement of prophylaxis. Indeed, many 
had, in fact, developed other serious co-morbidities during the course of their treatment, 
such as Hepatitis B/C or HIV, which may have also influenced their perceptions of medical 
interventions. 
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 The female relatives of AwH, however, viewed NGS from an entirely different vantage 
point. While not having experienced haemophilia directly themselves, the female relatives 
were nevertheless more heavily implicated, both socially as mothers, but also physically, as 
carriers, in their reproductive outcomes than their male counterparts, which may have 
affected their perceptions of their responsibilities with regards to their family’s health22. It is 
also possible that such family members may also have a more clear memory of a diagnostic 
odyssey, associated with later diagnosis, and may thus more clearly be able to envisage the 
benefits of early idenfication for boys with haemophilia.   We found similar differences 
between family members and AwH in our work on attitudes to pre-conception and pre-natal 
screening for haemophilia21. 
In spite of these differences between AwH and family members, however, support for NGS 
was nevertheless high. These findings, when interpreted alongside the qualitative data, 
suggest that the participants do not view haemophilia (even in its most severe form) to be a 
condition that justifies selective reproduction through pre-conception or prenatal screening 
programmes. Rather, our data suggest that participants perceived haemophilia as a 
‘liveable’ condition, and emphasised the importance of early identification (even if severity 
is initially unknown) in order to minimise the time to diagnosis and treatment, as well as to 
reduce the risks of intracranial bleeds and joint damage that can be associated with 
untreated haemophilia6.  
These findings are in line with our previous work assessing support for prenatal screening 
for haemophilia, which found that affected adults and their family members in support of 
this form of screening do so not because they believe that selective pregnancy termination 
is an essential option, but rather because they believe that prenatal screening can provide 
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vital information to prepare for the birth of a haemophiliac child, and also to protect the 
carrier mother5.  
However, in spite of this scepticism around the reproductive value of screening for 
haemophilia, there was nevertheless support for the idea that NGS could be used by the 
parents of already-affected children, to inform decisions about their future pregnancies. 
This finding is noteworthy as it suggests that the reproductive decisions and attitudes of 
already- affected families are viewed differently by the haemophilia community than those 
made by the general population, highlighting the positive way that ‘experiential knowledge’ 
and insight are valued in the appraisal of future affected lives23,24. Indeed, the families and 
adults who participated in this survey had direct-and often extensive- knowledge of life with 
haemophilia, with 136/327 participants (42%) (Table 3) of the sample having more than two 
people in their family living with haemophilia- a much higher rate of inter-family recurrence 
than has been noted by studies of screening attiudes within families affected by other 
genetic conditons 23.   
Overall, therefore, this study highlights the rich and complex insights that families living with 
genetic disorders bring to debates around expansive screening programmes. It is critical that 
any screening programme for haemophilia has an infrastructure that is able to capture and 
accurately reflect the reality of life with the condition, as this is likely to be different to the 
perceptions of haemophilia within the general public24.  The inclusion of families and AwH 
into screening policy debates is a key mechanism by which this change can occur.  
 
Further Research/Policy Implications 
This study underscores the importance of consulting affected families when evaluating and 
implementing genetic screening programmes. Indeed, these groups have much to offer an 
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understanding of the realities of genetic impairment, a form of knowledge that will only 
become more significant as genomic medicine expands and decisions will need to be made 
regarding which conditions should be included on genetic screening panels, and which 
should not. Indeed, further research could usefully explore the knowledge and views of the 
general public towards screening for haemophilia in order to identify differences and 
similarities in their perceptions of the condition, as well as to inform and facilitate the 
development of mechanisms of decision-support as reproductive decisions become 
invariably more complex for the whole of society.  
 
Strengths and Weaknesses 
Recruiting through a support group, and not clinics, may have imposed sample bias 
to the analysis as support groups are more likely to attract people experiencing difficulty, 
and those who value particular forms of support. Indeed, it is noteworthy that a high 
proportion of women with haemophilia (15%) participated in the study, which might be 
explained by the methods of recruitment, given that support groups are disproportionaltely 
accessed by women. Moreover, due to confidentiality and data protection requirements, no 
identifiable information was asked of participants. Whilst this may have aided recruitment, 
there was no means by which to prevent a participant from completing multiple surveys. In 
spite of these weaknesses, however, the final sample was nevertheless diverse.  
Given that participants were being asked about a hypothetical (rather than already 
implemented) screening programme, it is also possible that participants’ prior knowledge of 
NGS was limited, a fact that may have skewed their attitudes towards it. However, the 
current high profile of genomic medicine within the public and policy arena, the fact that all 
participants had prior experience of a genetic disease in their family as well as the relatively 
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recent introduction (2006) of an NGS in the UK for another genetic condition, Cystic Fibrosis, 
together meant that participants did not have to make large imaginative leaps to envisage 
the potential transferability of NGS to haemophilia, and as such, we do not feel that this lack 
of background knowledge need limit the value of the data.  
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Table 1: Characteristics and demographics of survey responders. Demographics are shown for all responders (n=327), responders associated 
with haemophilia families (families; n=148) and adults with haemophilia (AwH; n=179).  
 
  
Characteristic
All Responders 
(n=327)
Families (n=148) AwH (n=179)
Gender - no. (%)
Male 173 (53%) 21 (14%) 152 (85%)
Female 154 (47%) 127 (86%) 27 (15%)
Age
18-25 yr 11 (3%) 1 (1%) 10 (6%)
26-34 yr 38 (12%) 22 (15%) 16 (9%)
35-45 yr 68 (21%) 45 (30%) 23 (13%)
46-55 yr 60 (18%) 21 (14%) 39 (22%)
56-65 yr 65 (20%) 30 (20%) 35 (19%)
>65 yr 85 (26%) 29 (20%) 56 (31%)
Qualifications
Degree or higher 142 (43%) 70 (47%) 72 (40%)
Other / none 185 (57%) 78 (53%) 107 (60%)
Religious
Yes 183 (56%) 88 (60%) 95 (53%)
No 130 (40%) 55 (37%) 75 (42%)
Prefer not to say 14 (4%) 5 (3%) 9 (5%)
Parents
Yes 253 (77%) 135 (91%) 118 (66%)
No 73 (22%) 12 (8%) 61 (24%)
Prefer not to say 1 (1%) 1 (1%) 0
Type of Haemophilia
Haemophilia A 273 (83%) 127 (86%) 146 (82%)
Haemophilia B 54 (17%) 21 (14%) 33 (18%)
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Table 2: Response summaries for questions assessing views on newborn genetic screening (NGS). Response breakdowns are shown for families and AwH. Responses for each question were stratified as “agree” v 
“other” (other= disagree and neither disagree nor agree).  
 
  
All Responders 
(n=327)
Families 
(n=148)
AwH (n=179)
F v AwH (chi-
2)
Question P Value
Identifying haemophilia / bleeding disorders at birth would lead to better support and health care for the child and their family 0.66
Agree 291 (89%) 134 (91%) 157 (88%)
Other 36 (11%) 14 (9%) 22 (12%)
Identifying haemophilia / bleeding disorders at birth would extend the life expectancy of a child with a bleeding disorder 0.24
Agree 212 (65%) 91 (61%) 121 (68%)
Other 115 (35%) 57 (39%) 58 (32%)
Identifying haemophilia / bleeding disorders at birth (and not in pregnancy) takes away the parents right to make a decision 
about whether or not they want to have a child with a bleeding disorder 0.29
Agree 107 (33%) 44 (30%) 63 (35%)
Other 220 (67%) 104 (70%) 116 (65%)
Identifying haemophilia / bleeding disorders before a child develops any symptoms prevents the child and their family from 
enjoying life whilst they are still symptom-free 0.18
Agree 96 (29%) 38 (26%) 58 (32%)
Other 231 (71%) 110 (74%) 121 (68%)
Identifying haemophilia/bleeding disorders at birth would help research into a cure by enabling more children to be enrolled 
into clinical trials early on 0.93
Agree 198 (61%) 90 (61%) 108 (60%)
Other 129 (39%) 58 (39%) 71 (40%)
Identifying haemophilia / bleeding disorders at birth would interfere with the early bonding process between parent and child 0.36
Agree 18 (6%) 10 (7%) 8 (4%)
Other 309 (94%) 138 (93%) 171 (96%)
Identifying haemophilia / bleeding disorders at birth would make the diagnosis easier for parents to accept 0.17
Agree 177 (54%) 74 (50%) 103 (58%)
Other 150 (46%) 74 (50%) 76 (42%)
 Identifying haemophilia / bleeding disorders at birth would spare parents the difficulties associated with finding a diagnosis 
for the child later on 0.41
Agree 254 (78%) 118 (80%) 136 (76%)
Other 73 (22%) 30 (20%) 43 (24%)
Even if parents could not know for sure the severety of the haemophilia / bleeding disorder affecting their newborn baby, its 
still better that they know about the bleeding disorder straight away 0.63
Agree 284 (87%) 130 (88%) 154 (86%)
Other 43 (13%) 18 (12%) 25 (14%)
 Identifying haemophilia / bleeding disorders at birth is important as it would enable parents to make informed decisions about 
future pregnancies 0.45
Agree 266 (81%) 123 (83%) 143 (80%)
Other 61 (19%) 25 (17%) 36 (20%)
It is unethical not to screen newborn babies for conditions that can be treated 0.68
Agree 144 (44%) 67 (45%) 77 (43%)
Other 183 (56%) 81 (55%) 102 (57%)
I would support a newborn genetic screening programme for haemophilia / bleeding disorders 0.08*
Agree 253 (77%) 121 (82%) 132 (74%)
Other 74 (23%) 27 (18%) 47 (26%)
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Table 3: Support for NGS among families associated with increased numbers of people with haemophilia. The support was compared for responders associated with <2 affected individuals compared with those 
associated with  2+ affected individuals. Numbers and overall percentages are shown. Differences were assessed using chi-2 analysis (p-value).  
 
  
Other Agree Total
Associated with <2 affected individuals 42 (22%) 149 (78%) 191
Associated with 2+ affected individuals 32 (24%) 104 (76%) 136
327p=0.74
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Table 4: Response summaries for responders who did not support the introduction of NGS. Response breakdowns are shown for families and AwH. Responses for each question were stratified as “agree” v “other” 
(other= disagree and neither disagree nor agree). . Differences were assessed using chi-2 analysis (p-value). 
 
 
 
 
 
All Responders 
(n=74)
Families 
(n=27)
AwH (n=47) F v AwH 
Question P Value
Identifying haemophilia / bleeding disorders at birth would lead to better support and health care for the child and their family 0.63
Agree 44 (59%) 15 (56%) 29 (62%)
Other 30 (41%) 12 (44%) 18 (38%)
Identifying haemophilia / bleeding disorders at birth would extend the life expectancy of a child with a bleeding disorder 0.81
Agree 34 (46%) 13 (48%) 21 (45%)
Other 40 (54%) 14 (52%) 26 (55%)
Identifying haemophilia / bleeding disorders at birth (and not in pregnancy) takes away the parents right to make a decision 
about whether or not they want to have a child with a bleeding disorder 0.57
Agree 17 (23%) 5 (19%) 12 (26%)
Other 57 (77%) 22 (81%) 35 (74%)
Identifying haemophilia / bleeding disorders before a child develops any symptoms prevents the child and their family from 
enjoying life whilst they are still symptom-free 0.99
Agree 15 (20%) 5 (19%) 10 (21%)
Other 59 (80%) 22 (81%) 37 (79%)
Identifying haemophilia/bleeding disorders at birth would help research into a cure by enabling more children to be enrolled 
into clinical trials early on 0.41
Agree 18 (24%) 5 (19%) 13 (28%)
Other 56 (76%) 22 (81%) 34 (72%)
Identifying haemophilia / bleeding disorders at birth would interfere with the early bonding process between parent and child 0.99
Agree 6 (8%) 2 (7%) 4 (9%)
Other 68 (92%) 25 (93%) 43 (91%)
Identifying haemophilia / bleeding disorders at birth would make the diagnosis easier for parents to accept 0.79
Agree 22 (30%) 7 (26%) 15 (32%)
Other 52 (70%) 20 (74%) 32 (68%)
 Identifying haemophilia / bleeding disorders at birth would spare parents the difficulties associated with finding a diagnosis 
for the child later on 0.99
Agree 30 (41%) 11 (41%) 19 (40%)
Other 44 (59%) 16 (59%) 28 (60%)
Even if parents could not know for sure the severety of the haemophilia / bleeding disorder affecting their newborn baby, its 
still better that they know about the bleeding disorder straight away 0.47
Agree 40 (54%) 13 (48%) 27 (57%)
Other 34 (46%) 14 (52%) 20 (43%)
 Identifying haemophilia / bleeding disorders at birth is important as it would enable parents to make informed decisions about 
future pregnancies 0.47
Agree 39 (53%) 16 (59%) 23 (49%)
Other 35 (47%) 11 (41%) 24 (51%)
It is unethical not to screen newborn babies for conditions that can be treated 0.99
Agree 10 (14%) 4 (15%) 6 (13%)
Other 64 (86%) 23 (85%) 41 (87%)
Responders who do not support NGS
